Company news

Ovid Therapeutics Inc. news in 2020

Ovid Therapeutics Inc.'s news releases, calls and decks from 2020, newest first.

View company

Ovid Therapeutics Announces Addition to the Nasdaq Biotechnology Index

December 15, 2020

Ovid Therapeutics Announces Phase 3 NEPTUNE Clinical Trial of OV101 for the Treatment of Angelman Syndrome Did Not Meet Primary Endpoint

November 30, 2020

Ovid Therapeutics to Present at the American Epilepsy Society (AES) 2020 Virtual Congress

November 22, 2020

Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

November 11, 2020

Ovid Therapeutics to Host Educational Webinar on Angelman Syndrome and OV101 Development Program

October 13, 2020

Ovid Therapeutics to Present at the Child Neurology Society/International Child Neurology Association (CNS/ICNA) Virtual Congress

October 11, 2020

Ovid Therapeutics Provides Soticlestat (OV935/TAK-935) Results from ARCADE and ENDYMION Studies Showing Seizure Reduction in Rare Epilepsies

September 29, 2020

Ovid Therapeutics to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference

September 10, 2020

Phase 2 ELEKTRA Study of Soticlestat (TAK-935/OV935) Meets Primary Endpoint Reducing Seizure Frequency in Children with Dravet Syndrome or Lennox-Gastaut Syndrome

August 24, 2020

Ovid Therapeutics Announces Pricing of $50 Million Offering of Common Stock

August 24, 2020

Ovid Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

August 9, 2020

Ovid Therapeutics to Participate at the William Blair Biotech Focus Conference 2020

August 4, 2020

Ovid Therapeutics and University of Connecticut Enter into Strategic Research Collaboration to Accelerate the Development of Next-Generation Genetic Therapy for Angelman Syndrome

July 22, 2020

Ovid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 for the Treatment of Angelman Syndrome in Europe

July 12, 2020

Ovid Therapeutics Added to Russell 2000® and Russell 3000® Indexes

June 28, 2020

Ovid Therapeutics Receives FDA Rare Pediatric Disease Designation for OV101 for the Treatment of Angelman Syndrome

June 18, 2020

Ovid Therapeutics Announces Strategic Research Collaboration Focused on Accelerating the Development of New Treatments for Rare Neurological Diseases

June 10, 2020

Ovid Therapeutics Announces Multiple Presentations on the 2020 American Academy of Neurology Science Highlights Platform

June 7, 2020

Ovid Therapeutics Launches Pipeline Teach-In Webinar Series

June 3, 2020

Ovid Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

May 6, 2020

Ovid Therapeutics Announces Positive Topline Results from the Phase 2 ROCKET Trial of OV101 for the Treatment of Fragile X Syndrome

May 6, 2020

Ovid Therapeutics Announces Initial Data with Soticlestat in CDKL5 Deficiency Disorder and Dup15q Syndrome

March 29, 2020

Ovid Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results, Provides Corporate Update for 2020

March 10, 2020

Ovid Therapeutics Announces Multiple Presentations at the American Academy of Neurology 2020 Annual Meeting

March 4, 2020

Ovid Therapeutics Names Alexander Kolevzon, M.D., to Scientific Advisory Board

March 1, 2020

Ovid Therapeutics Provides 2020 Update in Preparation for Multiple Clinical Data Readouts Across Rare Neurological Disease Platform

January 6, 2020

Decks in 2020